ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WST

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1]. Group 1: Class Action Details - Investors who purchased West common stock between February 16, 2023, and February 12, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lead plaintiff must file a motion with the Court by July 7, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that West Pharmaceutical Services made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5]. - It is claimed that West was experiencing significant destocking in its high-margin products, contrary to its public statements attributing issues to temporary COVID-related factors [5]. - The operational inefficiencies of the SmartDose device reportedly diluted profit margins, leading to potential restructuring activities and exit from key contracts [5].